Dialysis News and Research

Latest Dialysis News and Research

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited , today announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure (CRF) patients on dialysis in the United States.

29 Nov 2010

Public health: Frequency of dialysis treatment questioned, chemotherapy drug shortages

A new study funded by the National Institutes of Health suggests that receiving dialysis six days a week results in better self-reported patient health than the conventional treatment of three times per week.

25 Nov 2010

DaVita announces emergency preparedness information for dialysis patients during winter season

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD) and end stage renal disease (ESRD), announced today important emergency preparedness information for dialysis patients during the upcoming winter season.

23 Nov 2010

Landmark comparative study supports more frequent hemodialysis

NxStage® Medical, Inc., a leading manufacturer of innovative dialysis products, today commented on the just- released findings of the Frequent Hemodialysis Network (FHN) Daily Trial that compared in-center hemodialysis administered under a three times per week schedule ("conventional dialysis") versus six shorter sessions per week ("short daily dialysis").

23 Nov 2010

Frequent hemodialysis improves left ventricular mass, physical health than conventional treatment

Frequent hemodialysis improved left ventricular mass (heart size) and self-reported physical health compared to conventional hemodialysis for kidney failure, according to the Frequent Hemodialysis Network (FHN) Daily Trial funded by the National Institutes of Health and the Centers for Medicare & Medicaid Services.

23 Nov 2010

DaVita announces meal planning tool for dialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease (ESRD) and chronic kidney disease (CKD), offers patients with very restricted diets an easy to use meal planning tool and recipes for their favorite Thanksgiving dinners at DaVita.com.

22 Nov 2010

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

On November 20 at the American Society of Nephrology 43rd Annual Meeting, Columbia University Assistant Professor of Clinical Medicine Andrew Bomback, MD, presented results from a patient case series assessing the potential therapeutic value of H.P. Acthar Gel (repository corticotropin injection) as a treatment for patients with nephrotic syndrome, a kidney disorder characterized by excessive loss of urinary protein.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Racial and socioeconomic disparities exist in kidney transplantation

Research shows that people with low incomes are more likely to develop kidney failure and less likely to receive a living donor kidney transplant than people of other socioeconomic classes.

22 Nov 2010

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Around a quarter of all heart attacks, strokes, and operations to open blocked arteries could be avoided in people with chronic kidney disease by using the combination of ezetimibe and simvastatin to lower blood cholesterol levels. That's the conclusion from the world's largest ever randomized trial in kidney disease.

22 Nov 2010

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.

22 Nov 2010

Inexpensive intervention helps patients with hypertension-associated kidney disease

In patients with kidney disease, the Western diet produces an acidic environment in the body that has numerous negative effects and worsens with age as kidney function declines.

21 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

Scientologists target Aborigines with “drug bombs”

The Northern Territory (NT) Health Department of Australia last Saturday warned the Church of Scientology that its drug detoxification therapy, being promoted to Aborigines in Australia by the church was dangerous for people with kidney problems.

21 Nov 2010

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Among kidney disease patients, earlier care from a nephrologist is associated with a decreased likelihood of developing end-stage renal disease and a lower risk of death during the first year of dialysis, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

20 Nov 2010

Early nephrology care associated with lower mortality and incidence of end stage renal disease

Earlier care from a nephrologist reduces the chance of kidney patients developing end-stage renal disease and lowers their risk of death during the first year of dialysis, according to a study by the University of Michigan Kidney Epidemiology & Cost Center.

20 Nov 2010

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that the Company will present new data at the American Society of Nephrology meeting being held in Denver, Colorado, on its late-stage investigational drug Soluble Ferric Pyrophosphate, which is being studied for the treatment of iron-deficiency anemia in ESRD patients.

20 Nov 2010

Study highlights poor outcomes for patients with ESRD admitted over weekend

Patients with end-stage renal disease who are admitted to the hospital during the weekend are at increased risk of death, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

20 Nov 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Dialysis News and Research

Latest Dialysis News and Research

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Public health: Frequency of dialysis treatment questioned, chemotherapy drug shortages

DaVita announces emergency preparedness information for dialysis patients during winter season

Landmark comparative study supports more frequent hemodialysis

Frequent hemodialysis improves left ventricular mass, physical health than conventional treatment

DaVita announces meal planning tool for dialysis patients

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

VYTORIN reduces major vascular events in patients with chronic kidney disease

Racial and socioeconomic disparities exist in kidney transplantation

SHARP study shows cholesterol-lowering effective for patients with kidney disease

Bardoxolone methyl treatment may reduce stage of CKD, improve eGFR in kidney function

Inexpensive intervention helps patients with hypertension-associated kidney disease

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Scientologists target Aborigines with “drug bombs”

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Early nephrology care associated with lower mortality and incidence of end stage renal disease

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Study highlights poor outcomes for patients with ESRD admitted over weekend

Merck wins third FOSAMAX bellwether trial

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dialysis News and Research

Latest Dialysis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in